Review the evidence on the effectiveness of Roflumilast and other PDE4 inhibitors in chronic inflammatory respiratory diseases beyond COPD including certain COPD phenotypes with comorbidities. Here, PDE4A is linked to chronic obstructive pulmonary disease.